A Prospective, Randomised, Placebo-controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Synovial Tissue

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2008 Jul 24

PMID 18647851

Citations 32

Authors

A W R van Kuijk

D M Gerlag

K Vos

G Wolbink

M de Groot

M A de Rie

A H Zwinderman

B A C Dijkmans

P P Tak

Affiliations

Soon will be listed here.

Abstract

Objective: To determine which of the changes in synovial tissue correlates best with clinical response associated with effective therapy (adalimumab) to facilitate the planning of future studies with therapeutic agents for psoriatic arthritis (PsA).

Methods: A total of 24 patients with active PsA were randomised to receive adalimumab (n = 12) or placebo (n = 12) for 4 weeks. Synovial biopsies were obtained before and after 4 weeks of treatment. Immunohistochemical analysis was performed to characterise the cell infiltrate, expression of cytokines and matrix metalloproteinases (MMPs) and vascularity. Sections were analysed by digital image analysis. Statistical analysis was performed using covariance analysis.

Results: The mean Disease Activity Score in 28 joints (DAS28) after 4 weeks was 1.92 units lower (95% confidence interval (CI) 1.07 to 2.77) after adalimumab therapy compared with placebo. Paired pretreatment and post-treatment synovial samples were available from 19 patients. Many cell types were reduced after adalimumab treatment compared to placebo. After applying a ranked analysis of covariance (ANCOVA) model to correct for baseline imbalances, a significant effect of treatment was observed on CD3-positive cells: there was a median reduction of 248 cells/mm(2) after adalimumab versus placebo treatment (p = 0.035). In addition, the expression of MMP13 was significantly reduced after active treatment: the integrated optical density (IOD)/mm(2) was 18 190 lower after adalimumab treatment as compared to placebo (p = 0.033).

Conclusion: Adalimumab therapy in PsA is associated with a marked reduction in T cell infiltration and MMP13 expression in synovial tissue, suggesting that these parameters could be used as biomarkers that are sensitive to change after active treatment in small proof of concept studies in PsA.

Citing Articles

Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis.

Montezuma T, Probst L, Almeida M Adv Rheumatol. 2024; 64(1):21.

PMID: 38515177 DOI: 10.1186/s42358-024-00361-3.

Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis.

Xie H, Zhang Y, Zhu Z, Wei J, Ainiwaer G, Ge W Rheumatol Ther. 2024; 11(2):269-283.

PMID: 38236456 PMC: 10920562. DOI: 10.1007/s40744-023-00636-z.

Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis.

Ciliento M, Venturelli V, Schettini N, Bertola R, Garaffoni C, Lanza G Int J Mol Sci. 2023; 24(5).

PMID: 36902437 PMC: 10002880. DOI: 10.3390/ijms24055006.

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis.

Bolt J, van Kuijk A, Teunissen M, van der Coelen D, Aarrass S, Gerlag D Biomedicines. 2022; 10(2).

PMID: 35203534 PMC: 8869729. DOI: 10.3390/biomedicines10020324.

Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies.

Martinez-Ramos S, Rafael-Vidal C, Pego-Reigosa J, Garcia S Cells. 2022; 11(3).

PMID: 35159323 PMC: 8834543. DOI: 10.3390/cells11030515.

References

Kraan M, Smith M, Weedon H, Ahern M, Breedveld F, Tak P . Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis. Ann Rheum Dis. 2001; 60(3):296-8. PMC: 1753569. DOI: 10.1136/ard.60.3.296. View

Gerlag D, Tak P . Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol. 2008; 22(2):311-23. DOI: 10.1016/j.berh.2008.02.002. View

Tak P, Bresnihan B . The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2001; 43(12):2619-33. DOI: 10.1002/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO;2-V. View

Smeets T, Barg E, Kraan M, Smith M, Breedveld F, Tak P . Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis. 2003; 62(7):635-8. PMC: 1754593. DOI: 10.1136/ard.62.7.635. View

Kraan M, Reece R, Smeets T, Veale D, Emery P, Tak P . Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum. 2002; 46(8):2034-8. DOI: 10.1002/art.10556. View

van Gestel A, Prevoo M, van t Hof M, van Rijswijk M, van de Putte L, van Riel P . Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against.... Arthritis Rheum. 1996; 39(1):34-40. DOI: 10.1002/art.1780390105. View

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54(8):2665-73. DOI: 10.1002/art.21972. View

Gerlag D, Haringman J, Smeets T, Zwinderman A, Kraan M, Laud P . Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum. 2004; 50(12):3783-91. DOI: 10.1002/art.20664. View

Boyle D, Rosengren S, Bugbee W, Kavanaugh A, Firestein G . Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res Ther. 2003; 5(6):R352-60. PMC: 333415. DOI: 10.1186/ar1004. View

10.

Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-35. DOI: 10.1002/art.1780380602. View

11.

Bresnihan B, Gerlag D, Rooney T, Smeets T, Wijbrandts C, Boyle D . Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol. 2007; 34(3):620-2. View

12.

Goedkoop A, Kraan M, Picavet D, de Rie M, Teunissen M, Bos J . Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther. 2004; 6(4):R326-34. PMC: 464872. DOI: 10.1186/ar1182. View

13.

Kruithof E, De Rycke L, Vandooren B, De Keyser F, FitzGerald O, McInnes I . Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum. 2006; 54(6):1795-804. DOI: 10.1002/art.21914. View

14.

Mease P, Gladman D, Ritchlin C, Ruderman E, Steinfeld S, Choy E . Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52(10):3279-89. DOI: 10.1002/art.21306. View

15.

Tak P, Smeets T, Daha M, Kluin P, MEIJERS K, Brand R . Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997; 40(2):217-25. DOI: 10.1002/art.1780400206. View

16.

Dolhain R, ter Haar N, de Kuiper R, Nieuwenhuis I, Zwinderman A, Breedveld F . Distribution of T cells and signs of T-cell activation in the rheumatoid joint: implications for semiquantitative comparative histology. Br J Rheumatol. 1998; 37(3):324-30. DOI: 10.1093/rheumatology/37.3.324. View

17.

Tak P . Lessons learnt from the synovial tissue response to anti-rheumatic treatment. Rheumatology (Oxford). 2000; 39(8):817-20. DOI: 10.1093/rheumatology/39.8.817. View

18.

Chandran V, Schentag C, Gladman D . Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 2007; 57(8):1560-3. DOI: 10.1002/art.23104. View

19.

Smeets T, Kraan M, Versendaal J, Breedveld F, Tak P . Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol. 1999; 26(10):2089-93. View

20.

Tracey D, Klareskog L, Sasso E, Salfeld J, Tak P . Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2007; 117(2):244-79. DOI: 10.1016/j.pharmthera.2007.10.001. View